Safety of Dental Extraction on New Oral Anticoagulants (NOACs) withouT Stopping Therapy (DENTST study)
Phase 4
Recruiting
- Conditions
- Dental extractionsAnticoagulationBlood - Other blood disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- Registration Number
- ACTRN12615001009505
- Lead Sponsor
- Dr Jennifer Curnow
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
1. Requires simple or surgical dental extraction(s).
2. On therapeutic dose of dabigatran, rivaroxaban, apixaban or warfarin.
3. Able to give informed consent.
4. Age 18 or above.
Exclusion Criteria
1. Women who are pregnant.
2. Concomitant use of dual anti-platelet therapy.
3. Inherited disorder of haemostasis.
4. Platelet count < 50 x 10^9/L.
5. Procedure for which operator requires OAC interruption.
6. OAC already ceased prior to procedure.
7. Patient on warfarin and INR < 2 or > 4.
8. Severe active oral infection associated with facial swelling.
9. Cockroft-Gaultcreatinine clearance < 25 ml/min for patients on dabigatran, < 30 ml/min for patients on rivaroxaban or apixaban.
11. Surgical extraction of wisdom teeth.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method